STOCKHOLM, Sweden--(BUSINESS WIRE)--July 10, 2006--Medivir (STO:MVIRB): Phase III study on Lipsovir® (ME-609) against labial herpes has started. New license agreement on HIV protease with Tibotec MIV-21 0 (HIV and hepatitis B) outlicensed to Tibotec for onward clinical development. Extended collaboration agreement on hepatitis C protease with Tibotec. Positive results from preclinical studies on the protease project against COPD. Consolidated net sales were SEK 18.5 (27.2) m in the period 1 January - 30 June 2006. The loss after tax was SEK -108.4 (-73.4) m; earnings per share were SEK -8.40 (-5.69). Forthcoming Financial Information